

Robyn P M Saw

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4002089/publications.pdf>

Version: 2024-02-01

111
papers

7,216
citations

81900

39
h-index

62596

80
g-index

112
all docs

112
docs citations

112
times ranked

9584
citing authors

#	ARTICLE	IF	CITATIONS
1	Whole-genome landscapes of major melanoma subtypes. <i>Nature</i> , 2017, 545, 175-180.	27.8	1,068
2	Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. <i>Cancer Cell</i> , 2019, 35, 238-255.e6.	16.8	547
3	BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact. <i>Clinical Cancer Research</i> , 2014, 20, 1965-1977.	7.0	447
4	Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 948-960.	10.7	346
5	CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment. <i>Clinical Cancer Research</i> , 2018, 24, 3036-3045.	7.0	297
6	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). <i>Nature Medicine</i> , 2021, 27, 301-309.	30.7	218
7	Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. <i>Nature Communications</i> , 2019, 10, 3163.	12.8	205
8	Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma. <i>Clinical Cancer Research</i> , 2017, 23, 5024-5033.	7.0	192
9	Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. <i>Nature Medicine</i> , 2021, 27, 256-263.	30.7	190
10	Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition. <i>Nature Communications</i> , 2020, 11, 1897.	12.8	165
11	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	10.7	155
12	Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. <i>Modern Pathology</i> , 2017, 30, 1666-1676.	5.5	150
13	Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 10995-11000.	7.1	146
14	Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. <i>Annals of Oncology</i> , 2018, 29, 1861-1868.	1.2	135
15	In-transit Melanoma Metastases: Incidence, Prognosis, and the Role of Lymphadenectomy. <i>Annals of Surgical Oncology</i> , 2015, 22, 475-481.	1.5	131
16	Neoadjuvant dabrafenib combined with trametinib for resectable, stage III B-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 961-971.	10.7	126
17	Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. <i>Nature Medicine</i> , 2022, 28, 1178-1188.	30.7	121
18	Outcome in 846 Cutaneous Melanoma Patients From a Single Center After a Negative Sentinel Node Biopsy. <i>Annals of Surgical Oncology</i> , 2005, 12, 429-439.	1.5	109

#	ARTICLE	IF	CITATIONS
19	Sentinel Lymph Node Biopsy in Patients With Thin Primary Cutaneous Melanoma. <i>Annals of Surgery</i> , 2012, 255, 128-133.	4.2	103
20	Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. <i>Nature Communications</i> , 2020, 11, 5259.	12.8	102
21	Keystone Flap Reconstruction of Primary Melanoma Excision Defects of the Leg—The End of the Skin Graft?. <i>Annals of Surgical Oncology</i> , 2008, 15, 2867-2873.	1.5	85
22	Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram. <i>Journal of Clinical Oncology</i> , 2020, 38, 2719-2727.	1.6	84
23	PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 6054-6061.	7.0	75
24	p53, Deleted in Colorectal Cancer Gene, and Thymidylate Synthase as Predictors of Histopathologic Response and Survival in Low, Locally Advanced Rectal Cancer Treated With Preoperative Adjuvant Therapy. <i>Diseases of the Colon and Rectum</i> , 2003, 46, 192-202.	1.3	72
25	Diagnosis of Metastatic Melanoma by Fine-Needle Biopsy. <i>American Journal of Clinical Pathology</i> , 2007, 127, 385-397.	0.7	72
26	Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1332-1342.	4.1	71
27	Workplace Bullying in Surgery. <i>World Journal of Surgery</i> , 2016, 40, 2560-2566.	1.6	69
28	A Sentinel Node Biopsy Does Not Increase the Incidence of In-Transit Metastasis in Patients With Primary Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2005, 12, 597-608.	1.5	67
29	Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. <i>Cancer Cell</i> , 2022, 40, 88-102.e7.	16.8	64
30	Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients. <i>Oncolmmunology</i> , 2020, 9, 1659093.	4.6	62
31	Proposed Quality Standards for Regional Lymph Node Dissections in Patients With Melanoma. <i>Annals of Surgery</i> , 2009, 249, 473-480.	4.2	61
32	Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. <i>Oncolmmunology</i> , 2019, 8, e1537581.	4.6	61
33	Imaging in cutaneous melanoma. <i>Nuclear Medicine Communications</i> , 2008, 29, 847-876.	1.1	60
34	Defining Lower Limb Lymphedema After Inguinal or Ilio-Inguinal Dissection in Patients With Melanoma Using Classification and Regression Tree Analysis. <i>Annals of Surgery</i> , 2008, 248, 286-293.	4.2	59
35	The Importance of Adequate Primary Tumor Excision Margins and Sentinel Node Biopsy in Achieving Optimal Locoregional Control for Patients With Thick Primary Melanomas. <i>Annals of Surgery</i> , 2013, 258, 152-157.	4.2	56
36	Molecular Genomic Profiling of Melanocytic Nevi. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1762-1768.	0.7	55

#	ARTICLE	IF	CITATIONS
37	Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility. <i>International Journal of Cancer</i> , 2019, 144, 1049-1060.	5.1	54
38	The Association Between Excision Margins and Local Recurrence in 11,290 Thin (T1) Primary Cutaneous Melanomas: A Caseâ€“Control Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 1082-1089.	1.5	43
39	Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation. <i>American Journal of Surgical Pathology</i> , 2016, 40, 786-795.	3.7	41
40	Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis. <i>Journal of Clinical Oncology</i> , 2017, 35, 1721-1729.	1.6	40
41	A qualitative assessment of psychosocial impact, coping and adjustment in high-risk melanoma patients and caregivers. <i>Melanoma Research</i> , 2014, 24, 252-260.	1.2	35
42	Primary Melanoma Location on the Scalp is an Important Risk Factor for Brain Metastasis: A Study of 1,687 Patients with Cutaneous Head and Neck Melanomas. <i>Annals of Surgical Oncology</i> , 2014, 21, 3985-3991.	1.5	35
43	1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study. <i>Annals of Surgical Oncology</i> , 2018, 25, 2541-2549.	1.5	35
44	Melanoma Patients with an Unknown Primary Tumor Site Have a Better Outcome than Those with a Known Primary Following Therapeutic Lymph Node Dissection for Macroscopic (Clinically Palpable) Nodal Disease. <i>Annals of Surgical Oncology</i> , 2014, 21, 3108-3116.	1.5	33
45	Neurotropic melanoma: an analysis of the clinicopathological features, management strategies and survival outcomes for 671 patients treated at a tertiary referral center. <i>Modern Pathology</i> , 2017, 30, 1538-1550.	5.5	33
46	p53, DCC and thymidylate synthase as predictors of survival after resection of hepatic metastases from colorectal cancer. <i>British Journal of Surgery</i> , 2002, 89, 1409-1415.	0.3	32
47	Minimum Safe Pathologic Excision Margins for Primary Cutaneous Melanomas (1â€“2Âmm in Thickness): Analysis of 2131 Patients Treated at a Single Center. <i>Annals of Surgical Oncology</i> , 2016, 23, 1071-1081.	1.5	31
48	Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas. <i>Oncotarget</i> , 2019, 10, 930-941.	1.8	31
49	Clinical and Pathologic Factors Associated with Distant Metastasis and Survival in Patients with Thin Primary Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 1782-1789.	1.5	30
50	Discrimination, Bullying and Harassment in Surgery: A Systematic Review and Metaâ€“analysis. <i>World Journal of Surgery</i> , 2018, 42, 3867-3873.	1.6	30
51	Patient Preferences for Follow-up After Recent Excision of a Localized Melanoma. <i>JAMA Dermatology</i> , 2018, 154, 420.	4.1	29
52	False-Positive Results and Incidental Findings with Annual CT or PET/CT Surveillance in Asymptomatic Patients with Resected Stage III Melanoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 1860-1868.	1.5	29
53	<i>BRAF</i> ^{V600E} and <i>NRAS</i> ^{Q61L/Q61R} mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. <i>Histopathology</i> , 2016, 69, 680-686.	2.9	28
54	Subungual Melanoma of the Hand. <i>Annals of Surgical Oncology</i> , 2019, 26, 1035-1043.	1.5	28

#	ARTICLE	IF	CITATIONS
55	Prevalence and Cellular Distribution of Novel Immune Checkpoint Targets Across Longitudinal Specimens in Treatment-naïve Melanoma Patients: Implications for Clinical Trials. <i>Clinical Cancer Research</i> , 2019, 25, 3247-3258.	7.0	27
56	The molecular profile of metastatic melanoma in Australia. <i>Pathology</i> , 2016, 48, 188-193.	0.6	26
57	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1429-1441.	1.6	23
58	Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. <i>Cancers</i> , 2020, 12, 2228.	3.7	22
59	Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma. <i>Annals of Oncology</i> , 2021, 32, 766-777.	1.2	22
60	Correlation Between Surgical and Histologic Margins in Melanoma Wide Excision Specimens. <i>Annals of Surgical Oncology</i> , 2019, 26, 25-32.	1.5	21
61	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). <i>Annals of Surgical Oncology</i> , 2022, 29, 3694-3708.	1.5	21
62	Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma. <i>JAMA Surgery</i> , 2022, 157, 335.	4.3	20
63	Quality assurance in melanoma surgery: The evolving experience at a large tertiary referral centre. <i>European Journal of Surgical Oncology</i> , 2015, 41, 830-836.	1.0	19
64	Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma. <i>Annals of Oncology</i> , 2020, 31, 1569-1579.	1.2	18
65	The Management of Cervical Lymph Nodes in Patients with Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 3926-3932.	1.5	17
66	Cross-cultural development of a quality-of-life measure for patients with melanoma. <i>Melanoma Research</i> , 2015, 25, 47-58.	1.2	16
67	Inter- and inpatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment. <i>Histopathology</i> , 2019, 74, 817-828.	2.9	16
68	Neoadjuvant ipilimumab plus nivolumab in synchronous clinical stage III melanoma. <i>European Journal of Cancer</i> , 2021, 148, 51-57.	2.8	16
69	Histological regression in melanoma: impact on sentinel lymph node status and survival. <i>Modern Pathology</i> , 2021, 34, 1999-2008.	5.5	16
70	Melanoma patient imaging in the era of effective systemic therapies. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1517-1527.	1.0	14
71	5-Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 249-255.	1.3	14
72	Metastatic Melanoma to the Colon, Rectum, and Anus: A 50-Year Experience. <i>Annals of Surgical Oncology</i> , 2018, 25, 2178-2183.	1.5	14

#	ARTICLE	IF	CITATIONS
73	Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma. <i>Cancers</i> , 2019, 11, 1905.	3.7	14
74	Reappraisal of the prognostic significance of mitotic rate supports its reincorporation into the melanoma staging system. <i>Cancer</i> , 2020, 126, 4717-4725.	4.1	14
75	Staging 18F-FDG PET/CT influences the treatment plan in melanoma patients with satellite or in-transit metastases. <i>Melanoma Research</i> , 2020, 30, 358-363.	1.2	14
76	Tumor Mutation Burden and Structural Chromosomal Aberrations Are Not Associated with T-cell Density or Patient Survival in Acral, Mucosal, and Cutaneous Melanomas. <i>Cancer Immunology Research</i> , 2020, 8, 1346-1353.	3.4	13
77	Implementation of patient-reported outcome measures and patient-reported experience measures in melanoma clinical quality registries: a systematic review. <i>BMJ Open</i> , 2021, 11, e040751.	1.9	13
78	The FACT-Melanoma Quality-of-Life Instrument. <i>Melanoma Research</i> , 2013, 23, 61-69.	1.2	12
79	The Optimum Excision Margin and Regional Node Management for Primary Cutaneous T3 Melanomas (2-4 mm in Thickness). <i>Annals of Surgery</i> , 2014, 260, 1095-1102.	4.2	12
80	Performance of Long-Term CT and PET/CT Surveillance for Detection of Distant Recurrence in Patients with Resected Stage IIIA-D Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 4561-4569.	1.5	11
81	Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/- Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets. <i>Cancers</i> , 2021, 13, 3186.	3.7	11
82	Multi-Trait Genetic Analysis Identifies Autoimmune Loci Associated with Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1607-1616.	0.7	11
83	Multiplex melanoma families are enriched for polygenic risk. <i>Human Molecular Genetics</i> , 2020, 29, 2976-2985.	2.9	9
84	Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 6109-6123.	1.5	8
85	Determining optimal sequencing of anti-PD-1 and BRAF-targeted therapy: A phase II randomised study of neoadjuvant pembrolizumab with/without dabrafenib and trametinib (D+T) in BRAF V600 mutant resectable stage IIIb/c/d melanoma (NeoTrio trial).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS9604-TPS9604.	1.6	8
86	Guidelines for imaging in cutaneous melanoma. <i>Nuclear Medicine Communications</i> , 2008, 29, 877-879.	1.1	7
87	Dramatic regression of cutaneous, nodal, and visceral melanoma metastases. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 665-666.	1.2	7
88	Development of the Melanoma Concerns Questionnaire (MCQ-28); refinement of the EORTC QLQ-MEL38 module. <i>Psycho-Oncology</i> , 2020, 29, 321-330.	2.3	7
89	Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy. <i>ANZ Journal of Surgery</i> , 2021, 91, 3-13.	0.7	7
90	Evaluation of Incomplete Sentinel Node Biopsy Procedures and Sentinel Node Positivity Rates as Surgical Quality-Assurance Parameters in Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2012, 19, 3919-3925.	1.5	6

#	ARTICLE	IF	CITATIONS
91	Rectal Cancer: Changing Patterns Of Referral For Radiation Therapy 1982-1997. Australian and New Zealand Journal of Surgery, 2000, 70, 553-559.	0.2	5
92	Clinical outcomes following surgical treatment of lentigo maligna of the head and neck. European Journal of Surgical Oncology, 2021, 47, 1145-1151.	1.0	5
93	The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma. Annals of Surgical Oncology, 2022, 29, 2871-2881.	1.5	5
94	Cost-effectiveness analysis of PET/CT surveillance imaging to detect systemic recurrence in resected stage III melanoma: study protocol. BMJ Open, 2020, 10, e037857.	1.9	4
95	Reply to: CT and PET/CT Surveillance in Stage IIIA-D Melanoma Results in More False-Positive Than True-Positive Findings and Should Not be Routinely Recommended, by Nicholas Taylor et al.. Annals of Surgical Oncology, 2021, 28, 819-820.	1.5	4
96	Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes. European Journal of Cancer, 2022, 167, 123-132.	2.8	4
97	Incidental detection of colorectal lesions by FDG PET/CT scans in melanoma patients. European Journal of Surgical Oncology, 2017, 43, 2163-2169.	1.0	3
98	Comprehensive molecular profiling of metastatic melanoma to predict response to monotherapy and combination immunotherapy.. Journal of Clinical Oncology, 2019, 37, 9511-9511.	1.6	3
99	BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. Pathology, 2022, 54, 6-19.	0.6	3
100	Treatment of in-transit melanoma metastases using intralesional PV-10. Melanoma Research, 2021, 31, 232-241.	1.2	2
101	Cutaneous sarcoidosis due to immune-checkpoint inhibition and exacerbated by a novel BRAF dimerization inhibitor. Skin Health and Disease, 0, , e71.	1.5	2
102	Melanoma and Quality of Life. , 2022, , 439-466.		2
103	Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. Frontiers in Oncology, 2022, 12, 820510.	2.8	2
104	Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. European Journal of Cancer, 2021, 153, 8-15.	2.8	1
105	Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre. Pathology, 2022, , .	0.6	1
106	Reflectance confocal microscopy â€œ a non-invasive tool for monitoring systemic treatment response in stage III unresectable primary scalp melanoma. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	2.4	1
107	Lower Lip Reconstruction Revisited: Technical Solutions to Prevent Oral Incontinence and Maximize Vermilion Anterior Projection. Plastic and Reconstructive Surgery, 2020, 146, 515e-516e.	1.4	0
108	Transcriptomic and immunophenotypic profiles of melanoma tissue from patients (pts) treated with anti-PD-1 +/- ipilimumab to define mechanisms of response and resistance.. Journal of Clinical Oncology, 2018, 36, 9518-9518.	1.6	0

#	ARTICLE	IF	CITATIONS
109	Diverse presentations of acral melanoma. Australian Family Physician, 2015, 44, 43-5.	0.5	0
110	OUP accepted manuscript. Journal of Surgical Case Reports, 2022, 2022, rjac172.	0.4	0
111	Effect of the <scp>SunSafe</scp> Training Program on the attitudes, knowledge, and behaviour of Australian high school students towards sun safety: a prospective study. Clinical and Experimental Dermatology, 2022, , .	1.3	0